BCL2 and B-cell chronic lymphocytic leukemia: The combination of the B-cell lymphoma 2 (BCL2) inhibitor venetoclax with antibodies against CD20, Obinutuzumab or Rituximab, has been shown to be an effective therapy for patients with CLL both in frontline therapy and after relapse [2].